Orchard Therapeutics’ Reports the US FDA’s Approval of Lenmeldy for the Treatment of Metachromatic Leukodystrophy (MLD)
Shots:
- The US FDA has granted approval to Lenmeldy (atidarsagene autotemcel) for treating children with early-onset metachromatic leukodystrophy (pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile)
- The approval was supported by the results from 2 early-onset MLD trials among pediatric patients (n=37) or the European expanded access program where patients received one-time gene therapy & compared with natural history data
- The >12yrs. follow-up data among earliest treated patients (median 6.76 years) showed extended OS along with preserved motor & cognitive function in late infantile MLD as well as early juvenile MLD patients
Ref: Orchard Therapeutics | Image: Orchard Therapeutics
Related News:- Kyowa Kirin to Acquire Orchard Therapeutics for ~$477.6M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
